$BCDA

Altman Peter purchased $415 of BCDA

Altman Peter (President and CEO) purchased 500 shares of BioCardia, Inc. (BCDA) at $0.83 on 2026-07-17.

Original reporting
SEC EDGAR · Altman Peter
Published Jul 20, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 12:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BCDA
Bullish
medium confidence
Mentioned
$BCDA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCDABullishLow
01

Why it matters

This is a primary-source insider buy by the CEO, but the disclosed size is modest and the filing contains no new business or financial information.

02

Market read

Traders may view the CEO’s open-market purchase as a small positive sentiment datapoint, but it is unlikely to drive a fundamental repricing without additional catalysts.

03

What to watch

The filing does not include any accompanying corporate update, guidance, or material event; without context on prior transactions, signal strength is limited.

Relevance 4/10Novelty 3/10Timing: Form 4 filed July 20, covering a July 17 purchase.

Background

The article is a SEC Form 4 insider transaction disclosure for BioCardia, Inc. (BCDA).

Company-level read

Ticker impact

$BCDABullishMedium confidence
Context

BioCardia CEO Altman Peter bought 500 shares in an open-market transaction at $0.8300/share, disclosed via Form 4 filed July 20.

Expected impact

Likely limited near-term price impact; any effect would be incremental sentiment rather than a catalyst.

Evidence & confidence

Form 4 confirms the transaction details (shares, price, total value) and insider role, but the article provides no operational or financial change that would re-rate the business.

Market effects

No sector read-through is provided beyond a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine, tax- or compensation-related, and the small $415 value may not signal a meaningful change in outlook.

Key entities

  • BioCardia, Inc.

    Company whose CEO insider purchase is disclosed on Form 4.

  • Altman Peter

    President and CEO who purchased 500 shares at $0.8300/share.

Related articles